Last mentioned: Feb 24, 2026
Earnings Release
Both companies report record Q4 results exceeding analyst guidance on revenue and EBITDA.
Debt Refinancing
BWXT completes $1.25B convertible debt raise to improve capital structure for 2026 expansion.
Fiscal Year End
BWXT Medical crosses $100M revenue threshold; Kratos hits record $1.57B backlog.
Kratos and BWXT reported strong Q4 2025 results, characterized by record-breaking backlogs and significant organic growth in specialized defense and commercial sectors. While BWXT is capitalizing on a massive surge in commercial nuclear demand, Kratos is seeing momentum in unmanned systems and space communications, signaling a robust outlook for high-tech defense contractors in 2026.
BWXT reported a record 85% surge in commercial nuclear backlog, while Kratos achieved 20% organic revenue growth, highlighting a massive shift toward high-density power and advanced propulsion technologies. These results underscore the growing 'Defense-Energy Nexus' as industrial and government sectors commit capital to next-generation reactor and turbine systems.
BWXT Technologies reported record Q4 2025 results, highlighted by its medical segment surpassing the $100 million revenue threshold amid a global expansion in nuclear medicine. The company's strategic pivot toward radiopharmaceuticals, supported by a $1.25 billion debt refinancing, positions it as a critical infrastructure provider for the next generation of targeted cancer therapies.
Kratos and BWXT both reported strong Q4 2025 results, highlighted by record-breaking backlogs and robust organic growth in high-tech defense segments. While Kratos capitalizes on unmanned systems and rocket support, BWXT is seeing a massive surge in commercial nuclear demand alongside its core naval propulsion business.